Medicine-induced Cardiac Hemodialysis on COVID-19

Yang I. Pachankis

Status and phase

Completed

Phase 4

Conditions

Vaccines

Infection Viral

Myocarditis Allergic

Severe Acute Respiratory Syndrome-related Coronavirus

Renal Dialysis

Treatments

Drug: Enalapril Maleate 10Mg Tab

Dietary Supplement: Omega-3

Behavioral: Low Mobility

Drug: Metoprolol Succinate

Diagnostic Test: Kangzhu BPCB0A-3A

Dietary Supplement: d-alpha tocopherol acetate

Drug: Nifedipine 30 MG

Dietary Supplement: Coenzyme Q10

Drug: Lansoprazole 30Mg Ec Cap

Drug: Duloxetine Hydrochloride 20 MG Oral Capsule, Delayed Release

Drug: Superoxide Dismutase

Study type

Interventional

Identifiers

NCT05711810

SARSCoVVaxPoison

Details and patient eligibility

About

The clinical trial studies the human pathogen of SARS-CoV-2, with a specificity in the circulating Spike 2 protein in the human system. The clinical trial hypothesizes that SARS-CoV-2 human pathogen arises from immune attacks, underlying the severe physiological symptoms that can be lethal. It further hypothesizes that the vaccines do not deal with the Spike 2 protein that causes the immune attacks.

Enrollment

1 patient

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

No mRNA vaccinated poisoning have been included currently, but scientific evidence suggest the methods of vaccination are irrelevant to the conditions. It is theorized that the more advanced the vaccine production technology, the deeper the poisoning.

Exclusion criteria

healthy individuals with no myocarditis or unvaccinated without infection by SARS-CoV series
persons with diabetes (Paxlovid and PrEP treatments can be applied according to availability)

Trial design

Primary purpose

Basic Science

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

1 participants in 1 patient group

Experiment Participant

Experimental group

Description:

COVID-19 recombined vaccinated, 3 dose, no intervention. Nifedipine, oral, 30 mg per day for 2 days, active comparative. Angiotensin-converting enzyme inhibitor, oral, gradually increase to 20 mg per day at night. Beta blocker, oral, 23.75 - 95 mg per day in the morning. Proton-pump inhibitor, oral, 30 mg per day. Duloxetine hydrochloride, oral, placebo, 20 mg per day before sleep. Acetaminophen (sham comparator), oral, 250 mg four times per day for 8 days. Cefuroxime (sham comparator), oral, 100 mg twice per day for 6 days. Papaverine, oral, low-dosage in coughing pills for 4 days. Superoxide Dismutase (active comparator), oral, to be introduced. Bafilomycin A1 (active comparator), oral, 100 ug per kilogram per day, unlikely to be introduced for lack of funding.

Treatment: